Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5‐hydroxytryptamine reuptake inhibitors in mice
Authors:
Open Access
- 1 September 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (2) , 276-284
Abstract
Background and purpose: Bridging the gap between preclinical research and clinical trials is vital for drug development. Predicting clinically relevant steady‐state drug concentrations (Css) in serum from preclinical animal models may facilitate this transition. Here we used a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to evaluate the predictive validity of 5‐hydroxytryptamine (5‐HT; serotonin) transporter (SERT) occupancy and 5‐hydroxytryptophan (5‐HTP)‐potentiated behavioral syndrome induced by 5‐HT reuptake inhibitor (SRI) antidepressants in mice. Experimental approach: Serum and whole brain drug concentrations, cortical SERT occupancy and 5‐HTP‐potentiated behavioral syndrome were measured over 6 h after a single subcutaneous injection of escitalopram, paroxetine or sertraline. [3H]2‐(2‐dimethylaminomethylphenylsulphanyl)‐5‐methyl‐phenylamine ([3H]MADAM) was used to assess SERT occupancy. For PK/PD modelling, an effect‐compartment model was applied to collapse the hysteresis and predict the steady‐state relationship between drug exposure and PD response. Key results: The predicted Css for escitalopram, paroxetine and sertraline at 80% SERT occupancy in mice are 18 ng mL−1, 18 ng mL−1 and 24 ng mL−1, respectively, with corresponding responses in the 5‐HTP behavioral model being between 20–40% of the maximum. Conclusions and implications: Therapeutically effective SERT occupancy for SRIs in depressed patients is approximately 80%, and the corresponding plasma Css are 6–21 ng mL−1, 21‐95 ng mL−1 and 20–48 ng mL−1 for escitalopram, paroxetine and sertraline, respectively. Thus, PK/PD modelling using SERT occupancy and 5‐HTP‐potentiated behavioral syndrome as response markers in mice may be a useful tool to predict clinically relevant plasma Css values. British Journal of Pharmacology (2008) 155, 276–284; doi:10.1038/bjp.2008.243; published online 16 June 2008Keywords
This publication has 30 references indexed in Scilit:
- Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulationThe AAPS Journal, 2005
- Selectivity of 3H‐MADAM binding to 5‐hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effectsBritish Journal of Pharmacology, 2004
- Escitalopram dose–response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depressionInternational Journal of Neuropsychopharmacology, 1999
- Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors???Clinical Pharmacokinetics, 1996
- Evidence-Based Health Policy—Lessons from the Global Burden of Disease StudyScience, 1996
- Cytochrome P450 EnzymesJournal of Clinical Psychopharmacology, 1996
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992
- Depression and Serotonin MetabolismJournal of Clinical Psychopharmacology, 1985
- Neurochemical Aspects of Depression: The Past and the Future?International Journal of Neuroscience, 1985